RLAY Research and Charts

RLAY - Relay Therapeutics Inc Ordinary Shares (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-05 (Delayed quote data 2025-01-06)

Last 4.57	Change ⇑ +0.15 (+3.39%)	Volume 1,952,403
	Open 4.44	High 4.66	Low 4.40

8EMA (Daily) 4.38	40EMA (Daily) 4.82	50EMA (Daily) 5.00	STO (Daily) 27.237	MACD Hist (Daily) 0.116
8EMA (Weekly) 4.714	40EMA (Weekly) 6.50	50EMA (Weekly) 7.01	STO (Weekly) 9.047	MACD Hist (Weekly) -0.126


Company Profile
Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.